Upcoming event

Tags

3D reconstruction, Article of the Month, Artificial intelligence, ASCO GU22, ASCO21, AUA21, augmented reality, biomarkers, Cabozantinib, Carcinoma, CheckMate-214, CheckMate-9ER, Checkpoint Inhibitor, Chronic kidney disease, clampless surgery, Cryosurgery, cystic masses, EAU, EAU21, EAU22, EMUC21, EMUC22, enucleoresection, ERUS 2026, ERUS22, ESMO21, ESMO25, expert interview, Frail patient​, Glomerular filtration rate, Guidelines, histology, imaging, IMDC risk model, International Metastatic Renal Cell Carcinoma Database Consortium, intraoperative cyst rupture, intraoperative ultrasound, Kidney cancer, Laparoscopy, localised renal cell carcinoma, Lymph node metastases, Lymph nodes, Metastasectomy, metastatic disease, metastatic RCC, Mortality, neoadjuvant immunotherapy, Neoplasm metastasis, Neoplasm recurrence, Nephrectomy, Nephron-sparing surgery, Nivolumab, Overall survival, papillary tumour, Partial nephrectomy, precision therapy, Prognostication, Radical nephrectomy, Radical surgery, RCC, Renal cancer, Renal cell, Renal cell carcinoma, Renal Cell Carcinoma guidelines, Renal cryoablation, Renal function, Renal Transplantation, Renorrhaphy, risk stratification, robot-assisted partial nephrectomy, Robotic, robotic partial nephrectomy, Robotic prostatectomy, Robotic surgery, selective clamping, stereotactic body radiation therapy, Survival outcome, Suture, sutureless partial nephrectomy, Targeted therapies, Treatment response, tumour enucleation, tumour genomics, tumour pseudocapsule rupture, Urological surgery, UROonco2025, UROonco24, UROonco25, UROwebinar, Webinar, zero-ischaemia surgery
Show all

Development and external validation of a new prognostic model for metastatic clear cell renal cell carcinoma: a preregistered analysis using data from randomised clinical trials in the checkpoint inhibitor era

The LANCET Oncology, September 2026

Adjuvant pembrolizumab plus belzutifan for renal-cell carcinoma

The New England Journal of Medicine, July 2026

Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials

THE LANCET Oncology, June 2026

KIM-1 in advanced papillary and clear cell renal cell carcinoma

European Urology, April 2026

Cambridge kidney One-Stop Mass Investigation Clinic (CkOSMIC): A nonrandomised feasibility study

European Urology Oncology, February 2026

Radiomics and image-based artificial intelligence for predicting recurrence and survival after surgery in localised renal cell carcinoma: An APPRAISE-AI systematic review and meta-analysis

European Urology Focus, January 2026

Kidney-sparing treatments for local recurrence in renal cell tumours after partial nephrectomy or focal therapy: A systematic review

European Urology Focus, December 2025

MLH1 mismatch repair deficiency predicts exceptional response to immune checkpoint inhibition in clear-cell renal cell carcinoma

European Urology, November 2025

Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial

The LANCET Oncology, October 2025

Urine glycosaminoglycan scores for surveillance of recurrence in intermediate- and high-risk nonmetastatic clear cell renal cell carcinoma – An observational prospective multicentre diagnostic test cohort study

European Urology Oncology, August 2025

Stereotactic body radiation therapy for primary renal cancer and genetic markers of response: A phase 2 trial

European Urology Oncology, June 2025

Exploratory analysis from NEOAVAX, a neoadjuvant trial of avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy

ASCO25, May 2025

Next